Evidence map›Paper›PMID 38699518›Full record

ReviewCambridge prisms. Precision medicine2024

Challenges and solutions to system-wide use of precision oncology as the standard of care paradigm.

Nesrine Lajmi, Sofia Alves-Vasconcelos, Apostolos Tsiachristas, Andrew Haworth, Kerrie Woods, Charles Crichton, Theresa Noble, Hizni Salih, Kinga A Várnai, Harriet Branford-White and 8 more

Abstract readReview
In one paragraph

Review in Cambridge prisms. Precision medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Nesrine LajmiDiagnostics Division, Roche Information Solutions, F. Hoffmann-La Roche Ltd., Basel, Switzerland.ORCID https://orcid.org/0009-0007-6575-5243
Sofia Alves-VasconcelosOxford Molecular Pathology Institute, Sir William Dunn School of Pathology, University of Oxford, Oxford, UK.
Apostolos TsiachristasNuffield Department of Primary Care Health Sciences, Radcliffe Observatory Quarter, Oxford, UK.
Andrew HaworthDiagnostics Division, Roche Information Solutions, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Kerrie WoodsOxford University Hospitals NHS Foundation Trust, Oxford, UK.
Charles CrichtonOxford University Hospitals NHS Foundation Trust, Oxford, UK.
Theresa NobleOxford University Hospitals NHS Foundation Trust, Oxford, UK.
Hizni SalihOxford University Hospitals NHS Foundation Trust, Oxford, UK.
Kinga A VárnaiOxford University Hospitals NHS Foundation Trust, Oxford, UK.
Harriet Branford-WhiteOxford University Hospitals NHS Foundation Trust, Oxford, UK.
Liam OrrellDiagnostics Division, Roche Information Solutions, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Andrew OsmanRoche Healthcare Consulting, Roche Diagnostics Limited, West Sussex, UK.
Kevin M BradleyWales Research and Diagnostic PET Imaging Centre, University Hospital of Wales, Cardiff, UK.
Lara BonneyOxford Molecular Pathology Institute, Sir William Dunn School of Pathology, University of Oxford, Oxford, UK.
Daniel R McGowanOxford University Hospitals NHS Foundation Trust, Oxford, UK.
Jim DaviesBig Data Institute, Li Ka Shing Centre for Health Information and Discovery, Oxford, UK.
Matthew S PrimeDiagnostics Division, Roche Information Solutions, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Andrew Bassim HassanOxford Molecular Pathology Institute, Sir William Dunn School of Pathology, University of Oxford, Oxford, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The personalised oncology paradigm remains challenging to deliver despite technological advances in genomics-based identification of actionable variants combined with the increasing focus of drug development on these specific targets. To ensure we continue to build concerted momentum to improve outcomes across all cancer types, financial, technological and operational barriers need to be addressed. For example, complete integration and certification of the 'molecular tumour board' into 'standard of care' ensures a unified clinical decision pathway that both counteracts fragmentation and is the cornerstone of evidence-based delivery inside and outside of a research setting. Generally, integrated delivery has been restricted to specific (common) cancer types either within major cancer centres or small regional networks. Here, we focus on solutions in real-world integration of genomics, pathology, surgery, oncological treatments, data from clinical source systems and analysis of whole-body imaging as digital data that can facilitate cost-effectiveness analysis, clinical trial recruitment, and outcome assessment. This urgent imperative for cancer also extends across the early diagnosis and adjuvant treatment interventions, individualised cancer vaccines, immune cell therapies, personalised synthetic lethal therapeutics and cancer screening and prevention. Oncology care systems worldwide require proactive step-changes in solutions that include inter-operative digital working that can solve patient centred challenges to ensure inclusive, quality, sustainable, fair and cost-effective adoption and efficient delivery. Here we highlight workforce, technical, clinical, regulatory and economic challenges that prevent the implementation of precision oncology at scale, and offer a systematic roadmap of integrated solutions for standard of care based on minimal essential digital tools. These include unified decision support tools, quality control, data flows within an ethical and legal data framework, training and certification, monitoring and feedback. Bridging the technical, operational, regulatory and economic gaps demands the joint actions from public and industry stakeholders across national and global boundaries.

Indexed as

cost-effectivenesshealth datainteroperabilitypatient centredpatient recordprecision medicineprecision oncologystandard of care

Identifiers

PMID38699518
PMCPMC11062796

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.